-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Analyzing Standard BioTools (NASDAQ:LAB) & Pacific Biosciences of California (NASDAQ:PACB)
Analyzing Standard BioTools (NASDAQ:LAB) & Pacific Biosciences of California (NASDAQ:PACB)
Standard BioTools (NASDAQ:LAB – Get Rating) and Pacific Biosciences of California (NASDAQ:PACB – Get Rating) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.
Profitability
This table compares Standard BioTools and Pacific Biosciences of California's net margins, return on equity and return on assets.
Get Standard BioTools alerts:Net Margins | Return on Equity | Return on Assets | |
Standard BioTools | -163.64% | -2,049.96% | -24.12% |
Pacific Biosciences of California | -218.44% | -42.03% | -15.59% |
Analyst Recommendations
This is a summary of current recommendations for Standard BioTools and Pacific Biosciences of California, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Standard BioTools | 0 | 0 | 0 | 0 | N/A |
Pacific Biosciences of California | 0 | 3 | 3 | 0 | 2.50 |
Insider & Institutional Ownership
63.2% of Standard BioTools shares are owned by institutional investors. Comparatively, 92.9% of Pacific Biosciences of California shares are owned by institutional investors. 51.6% of Standard BioTools shares are owned by insiders. Comparatively, 1.4% of Pacific Biosciences of California shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares Standard BioTools and Pacific Biosciences of California's gross revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Standard BioTools | $109.19 million | 1.51 | -$59.24 million | ($2.30) | -0.90 |
Pacific Biosciences of California | $130.51 million | 20.06 | -$181.22 million | ($1.34) | -8.64 |
Standard BioTools has higher earnings, but lower revenue than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Standard BioTools has a beta of 1.51, indicating that its stock price is 51% more volatile than the S&P 500. Comparatively, Pacific Biosciences of California has a beta of 1.67, indicating that its stock price is 67% more volatile than the S&P 500.
Summary
Pacific Biosciences of California beats Standard BioTools on 9 of the 13 factors compared between the two stocks.
About Standard BioTools
(Get Rating)
Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. It sells preparatory and analytical instruments for mass cytometry, polymerase chain reaction, library prep, single cell genomics, and consumables including integrated fluidic circuits (IFCs), assays, and reagents. The company was founded by Stephen D. Quake and Gajus Vincent Worthington on May 19, 1999 and is headquartered in South San Francisco, CA.
About Pacific Biosciences of California
(Get Rating)
Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. It operates through the following geographical segments: North America, Europe, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.
Receive News & Ratings for Standard BioTools Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Standard BioTools and related companies with MarketBeat.com's FREE daily email newsletter.
Standard BioTools (NASDAQ:LAB – Get Rating) and Pacific Biosciences of California (NASDAQ:PACB – Get Rating) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.
標準生物工具公司(納斯達克:LAB-GET評級)和加州太平洋生物科學公司(納斯達克:PACB-GET評級)都是醫療公司,但哪項業務更優越?我們將根據這兩家公司的股息、分析師建議、收益、風險、估值、盈利能力和機構持股情況對它們進行比較。
Profitability
盈利能力
This table compares Standard BioTools and Pacific Biosciences of California's net margins, return on equity and return on assets.
此表比較了標準生物工具公司和太平洋生物科學公司對加州淨利潤率、股本回報率和資產回報率的影響。
Net Margins | Return on Equity | Return on Assets | |
Standard BioTools | -163.64% | -2,049.96% | -24.12% |
Pacific Biosciences of California | -218.44% | -42.03% | -15.59% |
淨利潤率 | 股本回報率 | 資產回報率 | |
標準生物工具 | -163.64% | -2,049.96% | -24.12% |
加州太平洋生物科學 | -218.44% | -42.03% | -15.59% |
Analyst Recommendations
分析師建議
This is a summary of current recommendations for Standard BioTools and Pacific Biosciences of California, as provided by MarketBeat.com.
這是對加州標準生物工具和太平洋生物科學的當前建議的摘要,由MarketBeat.com提供。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Standard BioTools | 0 | 0 | 0 | 0 | N/A |
Pacific Biosciences of California | 0 | 3 | 3 | 0 | 2.50 |
銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
標準生物工具 | 0 | 0 | 0 | 0 | 不適用 |
加州太平洋生物科學 | 0 | 3 | 3 | 0 | 2.50 |
Insider & Institutional Ownership
內部人與機構所有權
63.2% of Standard BioTools shares are owned by institutional investors. Comparatively, 92.9% of Pacific Biosciences of California shares are owned by institutional investors. 51.6% of Standard BioTools shares are owned by insiders. Comparatively, 1.4% of Pacific Biosciences of California shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
標準生物工具63.2%的股份由機構投資者持有。相比之下,加州太平洋生物科學公司92.9%的股份由機構投資者持有。標準生物工具公司51.6%的股份由內部人士持有。相比之下,加州太平洋生物科學公司1.4%的股份由內部人士持有。強大的機構持股表明,捐贈基金、大型基金管理公司和對衝基金相信,一家公司的長期表現將好於大盤。
Valuation & Earnings
估值與收益
This table compares Standard BioTools and Pacific Biosciences of California's gross revenue, earnings per share (EPS) and valuation.
此表比較了標準生物工具公司和太平洋生物科學公司對加州總收入、每股收益(EPS)和估值的影響。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Standard BioTools | $109.19 million | 1.51 | -$59.24 million | ($2.30) | -0.90 |
Pacific Biosciences of California | $130.51 million | 20.06 | -$181.22 million | ($1.34) | -8.64 |
總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
標準生物工具 | 1.0919億美元 | 1.51 | -5924萬美元 | ($2.30) | -0.90 |
加州太平洋生物科學 | 1.3051億美元 | 20.06 | -1.8122億美元 | ($1.34) | -8.64 |
Standard BioTools has higher earnings, but lower revenue than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.
與加州的太平洋生物科學公司相比,標準生物工具公司的收益更高,但收入更低。加州太平洋生物科學的市盈率低於標準生物工具,表明它目前是兩隻股票中更負擔得起的一隻。
Volatility and Risk
波動性和風險
Standard BioTools has a beta of 1.51, indicating that its stock price is 51% more volatile than the S&P 500. Comparatively, Pacific Biosciences of California has a beta of 1.67, indicating that its stock price is 67% more volatile than the S&P 500.
Standard BioTools的貝塔係數為1.51,表明其股價的波動性比標準普爾500指數高出51%。相比之下,加州太平洋生物科學公司的貝塔係數為1.67,這表明其股價的波動性比標準普爾500指數高67%。
Summary
摘要
Pacific Biosciences of California beats Standard BioTools on 9 of the 13 factors compared between the two stocks.
在比較兩隻股票的13個因素中,加州太平洋生物科學公司在9個方面擊敗了標準生物工具公司。
About Standard BioTools
關於標準生物工具公司
(Get Rating)
(獲取評級)
Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. It sells preparatory and analytical instruments for mass cytometry, polymerase chain reaction, library prep, single cell genomics, and consumables including integrated fluidic circuits (IFCs), assays, and reagents. The company was founded by Stephen D. Quake and Gajus Vincent Worthington on May 19, 1999 and is headquartered in South San Francisco, CA.
標準生物工具公司致力於為臨牀研究提供生物技術工具和服務。它銷售用於質量細胞術、聚合酶鏈式反應、文庫準備、單細胞基因組學的準備和分析儀器,以及包括集成電路(IFCs)、分析和試劑在內的消耗品。該公司由斯蒂芬·D·奎克和加朱·文森特·沃辛頓於1999年5月19日創立,總部設在加利福尼亞州舊金山南部。
About Pacific Biosciences of California
關於加州的太平洋生物科學
(Get Rating)
(獲取評級)
Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. It operates through the following geographical segments: North America, Europe, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.
加利福尼亞太平洋生物科學公司致力於開發、製造和營銷用於基因分析的先進測序解決方案。它通過以下地理細分市場運營:北美、歐洲和亞太地區。該公司由斯蒂芬·特納和約瑟夫·文森特·邦文垂於2000年7月14日創立,總部設在加利福尼亞州門洛帕克。
Receive News & Ratings for Standard BioTools Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Standard BioTools and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《標準生物工具日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Standard BioTools和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧